Interferon Sciences plans to study Alferon N for MS, is in clinicals for HIV.
INTERFERON SCIENCES WILL TEST INTERFERON ALFA-N3 FOR MULTIPLE SCLEROSIS "once sufficient funding has been obtained," the New Brunswick, N.J.-based biotech reported in its recently-released 1994 annual report. Interferon Sciences, Inc. cited "significant adverse reactions" with Chiron/Berlex' Betaseron for relapsing-remitting multiple sclerosis as a factor in the decision to study its natural-source, human leukocyte-derived alpha interferon for the disease. ISI is the only manufacturer of natural source alpha interferon in the U.S.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth